Protracted chemotherapy regimens are new treatment modalities used to treat patients with cancer. These treatments are preferred because of the ease of administration and limited side effects in the outpatient setting. Sixty patients were treated with continuous infusion chemotherapy via implanted infusion ports at Marmara University Hospital Outpatient Chemotherapy Unit in Istanbul, Turkey, from January 2000 to December 2001. Although usage of Huber needles for central venous catheters was limited to between 48 and 72 hours, needles were not removed unless there were signs of inflammatory reaction. The needles remained in place for 28 days (1-49 days) on average. No catheter infections, signs of local irritation, or thrombus formation were observed despite prolonged stay of the Huber needles. Huber needles can be left in place up to several weeks without any untoward effects as long as proper aseptic technique is used.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00129804-200307000-00009 | DOI Listing |
Eur Urol Oncol
February 2025
Department of Biomedical Engineering, Yale University New Haven CT USA; Department of Radiology and Biomedical Imaging, Yale University New Haven CT USA; Department of Urology, Yale University New Haven CT USA. Electronic address:
Background And Objective: Conventional core needle biopsy for prostate cancer diagnosis can lead to diagnostic uncertainty and complications, prompting exploration of alternative risk assessment approaches that use clinical and imaging features. Our aim was to evaluate the effectiveness of machine learning (ML) models in reducing unnecessary biopsies.
Methods: We conducted a retrospective analysis of data for 1884 patients across two academic centers who underwent prostate magnetic resonance imaging and biopsy between 2016 and 2020 or 2004 and 2011.
Semin Intervent Radiol
June 2024
Department of Radiology, Interventional Radiology, University of Colorado, Aurora, Colorado.
Ultraschall Med
February 2025
Department for Internal Medicine, Red Cross Hospital Bremen, Bremen, Germany.
Am J Perinatol
May 2024
Department Women-Mother-Child, Clinic of Neonatology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Eur J Hosp Pharm
February 2025
Nantes Université, CHU Nantes, Pharmacie, Nantes, France.
Background: Totally implantable venous access port (TIVAP) is a type of implantable medical device that enables repetitive access to the intravenous system through use of a Huber needle. This device facilitates the administration of aggressive or long-term treatments while ensuring the comfort and safety of the patient. To ensure proper use of the medical device and lower the risk of complications, it is essential that patients acquire the necessary knowledge and skills regarding TIVAP.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!